Safety and Immunogenicity Study of Plasmodium Vivax CS Derived Synthetic Peptides Formulated in Two Adjuvants

Inclusion Criteria: * Healthy adults (male and non-pregnant female) 18- 45 years old, without previously malaria infection (naïve volunteers), capable to pass a comprehension test on the study and able to provide written informed consent to participate in the trial. * Use of adequate contraceptive method since the initiation of the study and until two months after the end of the study. * No plans to travel to a malaria endemic area during the course of the study. * Reachable by phone during the study period (1 year). * No use of other vaccines since 3 months before the beginning of the study and during it. Exclusion Criteria: * Females who intend to become pregnant within the 3 months following the screening visit or who are pregnant at screening time, ascertained by urine or serum pregnancy test (B-HCG). Women who are breast-feeding will also be excluded. Reason for exclusion: The immunological changes accompanying pregnancy and lactation could alter the results of the assays performed. If a pathological condition appear, it could be carried to the vaccine. * Duffy negative phenotype. Justification: Individuals with this phenotype are refractory to P. vivax infection. * G-6-PD deficiency or any genetic defect (hemoglobinopathy). Justification: These conditions influence the development of P. vivax infection. * History of previous experimental malaria vaccination. Justification: Individuals who have been previously immunized may show a response due to the past immunization and not to the present one. * Clinical or laboratory evidence of significant systemic disease, including hepatic, renal, cardiac, immunologic or hematological disease. Justification: The results of the study could have a negative impact on the study if volunteers are suffering from any of these diseases. * Evidence of active hepatitis B or C or HIV infection. Justification: Serious underlying medical condition could affect the immunological responses of volunteers or could increase the risk or severity of adverse events associated with participation in this study. * Clinically significant laboratory abnormalities as determined by the investigator(s). Justification: Baseline abnormal laboratory values may indicate a serious underlying medical condition and also will make it difficult to evaluate AE´s during the conduct of the study. • Known history of autoimmune (including inflammatory bowel disease, rheumatoid arthritis, lupus) or connective tissue disease. Justification: Autoimmune diseases could affect the immunological responses of volunteers and could increase the risk to the volunteer. • Individuals receiving treatment with steroids or non-steroidal anti-inflammatory drugs or any immunosuppressive therapy. Justification: These drugs could affect the immunological responses of volunteers and could increase the risk to the volunteer. * Known history of drug or alcohol abuse interfering with normal social function. Justification: Pharmaco-dependency alters the capacity of free decision and produce physical or psychiatric undesirable condition that could affect the study. * Volunteers unable to give written informed consent or with difficulties to understand the study. Justification: Volunteers must have the capacity to provide informed consent in order to participate in any research involving humans